Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
15 août 2024 08h00 HE
|
Tempest Therapeutics
Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and scheduleOverall survival, the strongest result from the Phase 2 trial, will be the primary study...
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 16h56 HE
|
Tempest Therapeutics
Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC”) study demonstrating: Survival benefit maintained across key subpopulationsa...
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
20 juin 2024 08h00 HE
|
Tempest Therapeutics
21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis...
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
18 juin 2024 18h22 HE
|
Tempest Therapeutics
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 juin 2024 04h30 HE
|
Tempest Therapeutics
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
Tempest to Participate in Upcoming Investor Conferences
21 mai 2024 08h00 HE
|
Tempest Therapeutics
BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 16h29 HE
|
Tempest Therapeutics
Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual MeetingPublished...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26 avr. 2024 16h05 HE
|
Tempest Therapeutics
BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
09 avr. 2024 08h00 HE
|
Tempest Therapeutics
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
04 avr. 2024 08h00 HE
|
Tempest Therapeutics
TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data,...